US20060199208A1 - Microarray device with optimized indicator polynucleotides - Google Patents

Microarray device with optimized indicator polynucleotides Download PDF

Info

Publication number
US20060199208A1
US20060199208A1 US11/361,627 US36162706A US2006199208A1 US 20060199208 A1 US20060199208 A1 US 20060199208A1 US 36162706 A US36162706 A US 36162706A US 2006199208 A1 US2006199208 A1 US 2006199208A1
Authority
US
United States
Prior art keywords
exon
indicator
polynucleotides
polynucleotide
array
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/361,627
Inventor
Subha Srinivasan
Jonathan Bingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jivan Biologics Inc
Original Assignee
Jivan Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/146,720 external-priority patent/US7340349B2/en
Application filed by Jivan Biologics Inc filed Critical Jivan Biologics Inc
Priority to US11/361,627 priority Critical patent/US20060199208A1/en
Publication of US20060199208A1 publication Critical patent/US20060199208A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6834Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

  • the described technology relates generally to selecting indicator polynucleotides and to detecting polynucleotides.
  • PCR analyses Polymerase chain reaction (PCR) analyses, nucleotide array experiments, in situ hybridizations, and Southern, Northern and Dot blot experiments attempt to form DNA-DNA, RNA-RNA, or DNA-RNA hybrids.
  • the melting temperature is the temperature at which 50% of a given indicator polynucleotide hybridizes to complementary polynucleotides of sufficient abundance.
  • the melting temperature is critical for determining the selectivity and sensitivity of indicator polynucleotides when used as primers in polymerase chain reaction (PCR) experiments, as probes for in situ hybridizations, as probes for nucleotide array experiments, and in Southern, Northern, or Dot blot experiments. If the melting temperature is too low, few indicator polynucleotides will hybridize to their complementary polynucleotides. If the melting temperature is too high, indicator polynucleotides may hybridize to polynucleotides weakly homologous to their complementary polynucleotides.
  • the formation of hybridization products may be influenced by experimental conditions and the nucleotide sequences of the indicator polynucleotide and the polynucleotides present in the biological sample or environment. It would be desirable to select indicator polynucleotides to maximize hybridization to complementary polynucleotides while minimizing hybridization to other polynucleotides. Also, it would be desirable if the post-hybridization analysis would factor in expected variations due to differing melting temperatures of indicator polynucleotides as well as expected variations due to homologous polynucleotides and other polynucleotides present in the sample or environment.
  • FIG. 1 is a flow diagram illustrating the overall process of selecting indicator polynucleotides to minimize the errors between the actual melting temperatures and the desired melting temperature in one embodiment.
  • FIG. 2 is a flow diagram illustrating the overall process of analytically correcting for variations in melting temperatures in one embodiment.
  • FIG. 3 is a flow diagram illustrating the overall process of correcting for hybridization of an indicator polynucleotide with a homologue of the target polynucleotide in one embodiment.
  • optimization techniques for selecting indicator polynucleotides for an experiment and for determining expression levels resulting from the experiment are provided.
  • the optimization technique corrects for variations in polynucleotide melting temperatures during analysis of the experimental results.
  • the optimization technique selects set of indicator polynucleotides for the experiment.
  • the optimization technique then performs the experiment with the indicator polynucleotides and a sample and identifies the relative amounts of the indicated polynucleotides.
  • the optimization technique then adjusts the relative amounts of the indicated polynucleotides based on melting temperatures associated with the indicator polynucleotides.
  • the optimization technique may increase the relative amount of the corresponding indicated polynucleotide to account for the high melting temperature.
  • the optimization technique includes a control indicator polynucleotide to identify relative amounts of a homologue polynucleotide whose presence is incidentally detected by an indicator polynucleotide designed to detect the presence of a target polynucleotide.
  • the optimization technique attempts to minimize the difference between the actual melting temperature of an indicator polynucleotide and a desired melting temperature.
  • the optimization technique attempts to minimize the overall error resulting from differences in the melting temperatures of the indicator polynucleotides and the desired melting temperature.
  • the optimization technique may modify indicator polynucleotides prior to performing an experiment to reduce the error.
  • the optimization technique may modify an indicator polynucleotide by shifting the location of an indicator polynucleotide to hybridize with upstream or downstream portions of the target polynucleotide.
  • the optimization technique may also vary the lengths of the indicator polynucleotides to minimize the error.
  • the optimization technique may attempt to balance the melting temperature for each exon portion of the indicator polynucleotide so that the indicator polynucleotide will hybridize to both exons equally.
  • the optimization technique selects indicator polynucleotides that tend to minimize the overall error in melting temperatures.
  • the optimization technique selects those indicator polynucleotides that minimize the value of E t given the desired melting temperature T d .
  • an example nucleotide array experiment involving indicator polynucleotides for each exon and exon-exon junction of a transcript of the gene CD44 with the GenBank locus name XM — 030326, which contains 18 exons and 17 exon-exon junctions, is used.
  • One indicator polynucleotide selection technique might select indicator polynucleotides with a length of 20 bases. Each indicator polynucleotide for an exon is selected to hybridize to the center of the exon, and each indicator polynucleotide for an exon-exon junction is selected to hybridize to 10 bases on each side of the exon-exon junction.
  • the NCBI locus name and version for the genomic sequence containing the CD44 gene is NT — 024229.8.
  • the NCBI locus name and version for the mRNA sequence of the CD44 transcript is XM — 030326.3.
  • the identifiers E1, E2, E3, and etc. identify indicator polynucleotides for exon 1, exon 2, exon 3, and etc.
  • the identifiers J1-2, J2-3, and etc. identify indicator polynucleotides for the exon-exon junction between exon 1 and exon 2, the exon-exon junction between exon 2 and exon 3, and etc.
  • L is the length of the target polynucleotide and GC is the GC content.
  • GC is the GC content.
  • the theoretical melting temperature can be calculated using various well-known equations. The calculated melting temperature varies from a low of 22° C. to a high of 62.03° C. in this example. This wide range of melting temperatures will lead to substantial variation in the number of polynucleotides that hybridize to instances of a given indicator polynucleotides in an experiment with fixed hybridization and washing temperatures. For example, in an experiment with a sample containing CD44 using a standard protocol with a hybridization temperature of 52° C. and a washing temperature of 52° C., the indicator polynucleotides with melting temperatures under 52° C.
  • indicator polynucleotides with low calculated melting temperatures may not bind to their target exons or exon-exon junctions with any measurable strength above a background level.
  • the optimization technique can optimize an indicator polynucleotide prior to running the experiment.
  • the optimization technique may optimize indicator polynucleotides by shifting the location of the indicator polynucleotides slightly upstream or downstream within their respective RNAs.
  • the optimization technique can select indicator polynucleotides for exons from any base range within the exon that the indicator polynucleotide identifies, using any selection criteria, such as GC content.
  • the optimization technique can optimize indicator polynucleotides by varying their lengths. For example, rather than selecting only indicator polynucleotides with a length of 20 bases, the optimization technique may select indicator polynucleotides of varying lengths to reduce the error measure for each indicator polynucleotide.
  • FIG. 1 is a flow diagram illustrating the overall process of selecting indicator polynucleotides to minimize the errors between the actual melting temperatures and the desired melting temperature in one embodiment.
  • the technique selects an initial set of indicator polynucleotides.
  • the technique inputs the desired melting temperature of the indicator polynucleotides.
  • the technique modifies each indicator polynucleotide to minimize its error.
  • the technique selects the next indicator polynucleotide.
  • decision block 104 if all the indicator polynucleotides have already been selected, then the technique completes, else the technique continues at block 105 .
  • decision block 105 if the error between actual melting temperature of the selected indicator polynucleotide and the desired melting temperature is acceptable, then the technique selects the next indicator polynucleotide, else the technique continues at block 106 .
  • the technique modifies the selected indicator polynucleotide using one or more of the described techniques (e.g., adjusting the length of the indicator polynucleotide or moving the indicator polynucleotide upstream or downstream) and then continues at a block 105 .
  • the error E t may be further reduced in a variety of ways, such as by introducing molecules other than the bases A, C, G, or T with different binding characteristics. Such bases may be appended, prepended, inserted, or selectively substituted within the indicator polynucleotides.
  • CD44 is known to have several splice variants.
  • the transcript used above contains several exons not present in other splice forms of CD44.
  • J6-7 does not exist in some species of CD44. Instead, E6 joins with a later exon E7′, yielding J6-7′.
  • the RNA transcript containing the J6-7 is referred to as R 1
  • the RNA transcript containing J6-7′ is referred to as R 2 .
  • binding may be less specific than desired if polynucleotides bind to one or the other half of an indicator polynucleotide. For example, if J6-7 is not present in a given sample, but E6 is present (because a different splice form of the gene is present in that sample), then an indicator polynucleotide for J6-7 may hybridize to E6 even though E6 is not joined to E7 in the splice variant in the sample. The hybridization, however, will likely be weaker than if a splice variant containing J6-7 was present.
  • the values in the matrix correspond to the expected expression level for the target polynucleotides.
  • the values in the correction matrix can be calculated or empirically derived.
  • the values can be empirically derived by performing a hybridization experiment containing J6-7′ but not J6-7.
  • the correction matrix may be derived using one or more samples containing antisense polynucleotides. A sample could include antisense polynucleotides for J6 or J7 or both.
  • J6 refers to the portion of an indicator polynucleotide for a J6-X junction that is used to identify the E6 portion of the junction.
  • an antisense polynucleotide for J6 might contain the complementary polynucleotide for J6.
  • the antisense polynucleotide might contain the complementary polynucleotide for J6 appended to a sequence of some additional number of bases, perhaps chosen randomly.
  • the antisense polynucleotide might contain J6 with J7 prepended.
  • J 6) 556 H ( J 6-7
  • J 7) 310 H ( J 6-7
  • J 6-7) 1544 H ( J 6-7
  • J 6, J 7) 756
  • J6) is the empirically derived expression level of the indicator polynucleotide for J6-7 in the presence of a sample containing antisense polynucleotides for J6,
  • J7) is the expression level of J6-7 in the presence of a sample containing antisense polynucleotides for J7
  • J6-7) is the ordinary expression level of J6-7 in the presence of antisense polynucleotides for J6-7
  • J6, J7) is the expression level of J6-7 in the presence of separate antisense polynucleotides for J6 and J7.
  • the expression values are not independent and are preferably measured in separate hybridization experiments. If more than one expression level is measured in the same experiment, the
  • M i,j H ( P i
  • M i,j is a coefficient matrix
  • P i an indicator polynucleotide that identifies a subsequence of RNA transcript R j
  • R j ) is the expression level of indicator polynucleotide P i given that RNA R j is expressed
  • H(P i ) is the expression level of the hybridization product of indicator polynucleotide i.
  • M 2,1 H ( J 6-7
  • M 2,2 H ( J 6-7
  • M 2,3 H ( J 6-7
  • J6-7) is the expression of the indicator polynucleotide for J6-7 given RNA containing J6-7 is present.
  • the remaining matrix elements all have a value of 1, for the same reason as M 2,1 .
  • the value 0.36 indicates that the indicator polynucleotide for J6-7 will yield a relative expression level of 0.36 times the full value if R 2 is present, and the other two splice variants are not present.
  • the expression level is non-zero in this case because the indicator polynucleotide for J6-7 will hybridize weakly in the presence of E6 even if J6-7 is not present.
  • the value 0.49 indicates that the indicator polynucleotide for J6-7 will yield a relative expression level of 0.49 times the full value if R 3 is present and the other two splice variants are not present.
  • the value for J6-7 in R 3 is larger than the corresponding value in R 2 because the indicator polynucleotide will hybridize weakly to both E6 and E7 rather than only to E6. Modifying a Junction Indicator Polynucleotide to Balance Its Melting Temperature
  • the indicator polynucleotide for J6-7 consists of a portion J6 that identifies the 3′ end of E6 as well as a portion J7 that identifies the 5′ end of E7. Each of these portions has its own melting temperature. In other words, the indicator polynucleotide for J6-7 will hybridize to E6 based on the melting temperature of J6 even if J6-7 is not present in the sample. Likewise, the indicator polynucleotide will hybridize to E7 based on the melting temperature of J7 even if J6-7 is not present in the sample. In one embodiment, the optimization technique balances the melting temperature of each exon portion of a junction indicator polynucleotide.
  • a full set of exon-exon junction indicator polynucleotides with a length of 30 bases for CD44 selected to have 15 bases for each exon is shown in the following: TABLE 3 Junction/ Melting Left Melting Right Melting SEQ ID No Exon Temp ° C. Temp ° C. Temp ° C.
  • the temperature difference in J6-7 is approximately 5.5° C.
  • the expected result of the difference is that the indicator polynucleotide will yield a larger expression value if E6 is present without J6-7 than if E7 is present without J6-7.
  • a similar effect will be observed to varying degrees for all of the indicator polynucleotides.
  • the optimization technique corrects for these effects using the linear equations presented above. For example, different values for a transcript containing E6 but not E7 than for a transcript containing E7 but not E6 may be used.
  • R 2 is a transcript containing E6 but not E7
  • R 3 is a transcript containing E7 but not E6.
  • the optimization technique minimizes or eliminates the need for this correction by balancing the melting temperature on each side of the exon-exon junction, so that the melting temperatures of indicator polynucleotide portions J6 and J7 are close to equal.
  • E x 2 ( T ia ⁇ T ib ) 2 (7)
  • E x is the error from imbalance in melting temperature
  • T ia is the calculated or empirical melting temperature of the portion of the indicator polynucleotide which identifies the 3′ end of the first exon
  • T ib is the calculated melting temperature of the portion of the indicator polynucleotide which identifies the 5′ end of the second exon. If the indicator polynucleotide does not identify an exon-exon junction, the error is zero.
  • E xt 2 E x1 2 +E x2 2 + . . .
  • E xt is the total error from multiple indicator polynucleotides as a result of temperature imbalance in indicator polynucleotides that identify exon-exon junctions.
  • error metrics other than Euclidean distance may be used.
  • E jt is the total error from both temperature imbalance in exon-exon junction indicator polynucleotides and each E ji is the error for each individual indicator polynucleotide i calculated using equation 9.
  • error metrics other than Euclidea distance can be used and that equations 7-10 can be generalized as equations 3 and 4 were generalized.
  • the temperature balancing technique has eliminated over 95% of the variability in melting temperature between the two portions of each exon-exon junction indicator polynucleotide as compared to the indicator polynucleotide selection technique.
  • the melting temperature of a fixed-length indicator polynucleotide can be balanced by decreasing the length of one exon's portion and increasing the length of the other exon's portion.
  • the length of the indicator polynucleotide for a junction is 20 and the length of each portion is 10, then the length of one portion may be decreased to 8 and the length of the other portion might be increased to 12 to balance the melting temperature, keeping the overall length at 20. Corrections can be applied to experimental results, as described above, to further reduce the variability.
  • the optimization technique corrects for variations in polynucleotide melting temperatures during analysis of the experimental results.
  • FIG. 2 is a flow diagram illustrating the overall process of analytically correcting for variations in melting temperatures in one embodiment. The steps of the processes illustrated by the flow diagrams may be controlled by, performed with the assistance of, or performed by a computer system. One skilled in the art will appreciate that various steps may be performed manually.
  • the technique selects the indicator polynucleotides that are to be used to identify target polynucleotides in a sample.
  • the technique performs the hybridization experiment, for example, using nucleotide array technology.
  • the technique receives the resulting expression levels from the experiment.
  • the technique calculates or inputs the melting temperature for each of the indicator polynucleotides.
  • the technique adjusts the expression levels based on the melting temperature for each of the indicator polynucleotides and temperature (e.g., hybridization temperature or wash temperature) at which the experiment was performed to give the final calculated expression levels for the experiment.
  • temperature e.g., hybridization temperature or wash temperature
  • matrix M might consist entirely of zeros and ones.
  • the value of 0 indicates the expected expression level will be zero if the target polynucleotide (e.g., J6-10) is not present in the sample.
  • the uniform value of 1 indicates the expected expression levels of all other indicator polynucleotides will be equal if the expected RNA transcript is present in the sample.
  • the indicator polynucleotides may identify their target polynucleotides at varying expression levels because of variations in the melting temperature of the indicator polynucleotides.
  • the optimization technique adjusts the detected expression levels to account for the variations in melting temperatures.
  • the optimization technique performs the correction by adjusting the detected expression levels of matrix H, rather than adjusting the coefficients of matrix M.
  • the optimization technique in one embodiment may apply a correction based on one or more empirical hybridization experiments.
  • One such experiment creates a sample consisting of synthesized polynucleotides to bind to indicator polynucleotides on a nucleotide array.
  • k is 1/1208 resulting in a corrected expected expression level of 1.23 (e.g., (1/1208)*1481).
  • the optimization technique can also correct for 3′ bias, which occurs in some methods of RNA amplification, such as T7 amplification.
  • the optimization technique can use more complex functions when the expression level varies nonlinearly with respect to the distance from the 3′ end. For example, the expression level might drop precipitously when b exceeds some value.
  • the optimization technique can use a nonlinear equation to represent such a drop.
  • H′ i,j H i,j *( C 1 i,j ) ⁇ 1 *( C 2 i,j ) ⁇ 1 * . . . *( C n i,j ) ⁇ 1 (21)
  • H′ i,j f ( H i,j , C 1 i,j , C 2 i,j , . . . , C n i,j ) (22) where f is a function that applies each individual correction to the empirically derived expression level.
  • the optimization technique corrects for the presence of homologous polynucleotides in a sample.
  • an indicator polynucleotide identifies a target polynucleotide in an RNA transcript, but it may also identify, albeit less strongly, a homologue of the target polynucleotide in a different RNA transcript.
  • the RNA transcripts may differ by only a few bases.
  • the optimization technique can correct for a homologue in the sample by adding a column to matrix M for the homologue. The column might have a value only in row i if no other indicator polynucleotide in the experiment identifies a subsequence of the different RNA transcript.
  • the solution can be found in various ways, such as using a system of linear equations or a least squares algorithm as described above.
  • the optimization technique may determine the contribution to the expression level of the indicator polynucleotide resulting from the homologue if the expression level of the homologue by itself is known. Such determination would not have to rely on a single indicator polynucleotide to identify the expression level of both the target polynucleotide and the homologue.
  • the optimization technique can determine the expression level of the homologue by selecting one or more “control indicator polynucleotides” specific to the homologue.
  • FIG. 3 is a flow diagram illustrating the overall process of correcting for hybridization of an indicator polynucleotide with a homologue of the target polynucleotide in one embodiment. In block 301 , the technique selects the indicator polynucleotide.
  • the technique selects a control polynucleotide.
  • the technique performs the experiment using the indicator polynucleotide and a control indicator polynucleotide.
  • the technique retrieves the expression levels from the experiment.
  • the technique adjusts the expression levels based on the characteristics of the control indicator polynucleotide.
  • the optimization techniques can identify control indicator polynucleotides by selecting a region of the 3′ untranslated of the homologue, confirming that it has no homologues by performing a similarity search (such as a BLAST search) against a database of known sequences, and designing control indicator polynucleotide to identify that region.
  • the optimization technique includes this control indicator polynucleotide in the experiment to correct the original indicator polynucleotide that may be weakly identifying the homologue instead of or in addition to the target polynucleotide.
  • the constant k accounts for differences between the target polynucleotide and its homologue.
  • the contribution of the homologous polynucleotide to the expression level measured for an indicator polynucleotide P i will be less than its independent expression level as measured by the control indicator polynucleotide.
  • the value of k may be determined empirically by performing hybridizations with the homologous polynucleotide and the indicator polynucleotide whose expression level is the numerator of k and with the homologous polynucleotide and the control indicator polynucleotide whose expression level is the denominator of k.
  • N′ i ) f ( P i , N′ i ) (24)
  • N′ i ) is the empirically derived expression level of polynucleotide P i when hybridized to a sample containing polynucleotide N′ i
  • f(P i , N′ i ) is a function of the two polynucleotides that are binding.
  • the function f may take into consideration various factors such as the number of matches, the individual melting temperatures of the polynucleotides assuming perfect matches, base stacking, salt concentration, GC content, the precise pairing of mismatched bases, number of hydrogen bonds, magnesium concentration, primer concentration, length of perfectly matching regions, melting temperature of perfectly matching regions, distance of mismatches from the ends of the polynucleotides, and so on.
  • the optimization technique corrects for an indicator polynucleotide that identifies a target polynucleotide and its homologue.
  • the control indicator polynucleotide is used to determine the independent expression level of the RNA containing the homologue.
  • the optimization technique calculates the value of the constant k as 0.723.

Abstract

Optimization techniques for selecting indicator polynucleotides for an experiment and for determining expression levels resulting from the experiment. The optimization technique corrects for variations in polynucleotide melting temperatures during analysis of the experimental results. The optimization technique selects set of indicator polynucleotides for the experiment. The optimization technique then performs the experiment with the indicator polynucleotides and a sample and identifies the relative amounts of the indicated polynucleotides. The optimization technique then adjusts the relative amounts of the indicated polynucleotides based on melting temperatures associated with the indicator polynucleotides.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. patent application Ser. No. 10/272,461, entitled METHODS AND SYSTEMS FOR POLYNUCLEOTIDE DETECTION, filed Oct. 16, 2002, now pending; which is a continuation-in-part of U.S. patent application Ser. No. 10/146,720, entitled A METHOD TO ASSEMBLE SPLICE VARIANTS FOR BOTH KNOWN AND PREDICTED GENES, A METHOD FOR VALIDATING THEIR EXPRESSION IN CELLS AND A METHOD OF DISCOVERING NOVEL EXON/EXON EXTENSIONS/TRIMS, filed May 14, 2002, now pending, which claims the benefit of U.S. Provisional Patent Application No. 60/307,911, entitled A METHOD TO ASSEMBLE SPLICE VARIANTS FOR BOTH KNOWN AND PREDICTED GENES, A METHOD FOR VALIDATING THEIR EXPRESSION IN CELLS AND A METHOD OF DISCOVERING NOVEL EXON/EXON EXTENSIONS/TRIMS, filed Jul. 25, 2001, now abandoned; the Ser. No. 10/146,720 application also claim the benefit of U.S. Provisional Patent Application No. 60/343,298, entitled METHODS OF OLIGO SELECTION AND OPTIMIZATION, filed Dec. 21, 2001, now abandoned; and U.S. Provisional Patent Application No. 60/329,914, entitled A METHOD TO ASSEMBLE SPLICE VARIANTS FOR BOTH KNOWN AND PREDICTED GENES, A METHOD FOR VALIDATING THEIR EXPRESSION IN CELLS AND A METHOD OF DISCOVERING NOVEL EXON/EXON EXTENSIONS/TRIMS, filed Oct. 17, 2001, now abandoned, all of which are hereby incorporated by reference in their entirety.
  • TECHNICAL FIELD
  • The described technology relates generally to selecting indicator polynucleotides and to detecting polynucleotides.
  • BACKGROUND
  • Polymerase chain reaction (PCR) analyses, nucleotide array experiments, in situ hybridizations, and Southern, Northern and Dot blot experiments attempt to form DNA-DNA, RNA-RNA, or DNA-RNA hybrids. In such experiments, an “indicator polynucleotide,” such as an oligonucleotide probe, hybridizes to a polynucleotide that includes a polynucleotide subsequence complementary to the indicator polynucleotide. The “melting temperature,” which depends in part upon the nucleotide sequence of the indicator polynucleotide, characterizes the stability of the hybridization product given a set of experimental conditions. The melting temperature is the temperature at which 50% of a given indicator polynucleotide hybridizes to complementary polynucleotides of sufficient abundance. The melting temperature is critical for determining the selectivity and sensitivity of indicator polynucleotides when used as primers in polymerase chain reaction (PCR) experiments, as probes for in situ hybridizations, as probes for nucleotide array experiments, and in Southern, Northern, or Dot blot experiments. If the melting temperature is too low, few indicator polynucleotides will hybridize to their complementary polynucleotides. If the melting temperature is too high, indicator polynucleotides may hybridize to polynucleotides weakly homologous to their complementary polynucleotides. Even with an optimal melting temperature, the formation of hybridization products may be influenced by experimental conditions and the nucleotide sequences of the indicator polynucleotide and the polynucleotides present in the biological sample or environment. It would be desirable to select indicator polynucleotides to maximize hybridization to complementary polynucleotides while minimizing hybridization to other polynucleotides. Also, it would be desirable if the post-hybridization analysis would factor in expected variations due to differing melting temperatures of indicator polynucleotides as well as expected variations due to homologous polynucleotides and other polynucleotides present in the sample or environment.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 is a flow diagram illustrating the overall process of selecting indicator polynucleotides to minimize the errors between the actual melting temperatures and the desired melting temperature in one embodiment.
  • FIG. 2 is a flow diagram illustrating the overall process of analytically correcting for variations in melting temperatures in one embodiment.
  • FIG. 3 is a flow diagram illustrating the overall process of correcting for hybridization of an indicator polynucleotide with a homologue of the target polynucleotide in one embodiment.
  • DETAILED DESCRIPTION
  • Optimization techniques for selecting indicator polynucleotides for an experiment and for determining expression levels resulting from the experiment are provided. In one embodiment, the optimization technique corrects for variations in polynucleotide melting temperatures during analysis of the experimental results. The optimization technique selects set of indicator polynucleotides for the experiment. The optimization technique then performs the experiment with the indicator polynucleotides and a sample and identifies the relative amounts of the indicated polynucleotides. The optimization technique then adjusts the relative amounts of the indicated polynucleotides based on melting temperatures associated with the indicator polynucleotides. For example, if one of the indicator polynucleotides has a high melting temperature relative to the hybridization and wash temperatures, then the optimization technique may increase the relative amount of the corresponding indicated polynucleotide to account for the high melting temperature. In an alternate embodiment, the optimization technique includes a control indicator polynucleotide to identify relative amounts of a homologue polynucleotide whose presence is incidentally detected by an indicator polynucleotide designed to detect the presence of a target polynucleotide.
  • In another embodiment, the optimization technique attempts to minimize the difference between the actual melting temperature of an indicator polynucleotide and a desired melting temperature. When multiple indicator polynucleotides are used in a single experiment, the optimization technique attempts to minimize the overall error resulting from differences in the melting temperatures of the indicator polynucleotides and the desired melting temperature. The optimization technique may modify indicator polynucleotides prior to performing an experiment to reduce the error. The optimization technique may modify an indicator polynucleotide by shifting the location of an indicator polynucleotide to hybridize with upstream or downstream portions of the target polynucleotide. The optimization technique may also vary the lengths of the indicator polynucleotides to minimize the error. When detecting exon-exon junctions, the optimization technique may attempt to balance the melting temperature for each exon portion of the indicator polynucleotide so that the indicator polynucleotide will hybridize to both exons equally. These and another optimization techniques are described more fully in the following.
  • Measuring Error in Melting Temperatures
  • In one embodiment, the optimization technique selects an indicator polynucleotide from among multiple possibilities that will minimize an error equation, such as the following distance equation:
    E 2=(T d −T m)   (1)
    where E is the error, Td is the desired melting temperature, and Tm is the theoretical or empirical melting temperature of the polynucleotide. Equation 1 is generally referred to as an Euclidean distance measure. The indicator polynucleotide with the smallest error may be the best choice.
  • When multiple indicator polynucleotides are to be used in the same experiment, the optimization technique selects indicator polynucleotides that tend to minimize the overall error in melting temperatures. In one embodiment, the optimization technique calculates the error according to the following equation.
    E t 2 =E 1 2 +E 2 2 + . . . +E n 2  (2)
    where Et is the total error, Ei is the error from the ith polynucleotide, and n is the number of indicator polynucleotides.
  • A more general formulation of error equation 1 that applies to a single polynucleotide is the following equation:
    E=f(T d , T m)   (3)
    where f is any arbitrary error function. The substitution of equation 3 into equation 2 for multiple polynucleotides results in the following equation:
    E t =g(f(T d , T m1), f(T d , T m2), . . . , f(T d , T mn))   (4)
    where g is a function that combines the individual error measures of the n indicator polynucleotides. When an experimental design includes constraints, such as which genes, exons, or exon-exon junctions the indicator polynucleotides identify, the optimization technique selects those indicator polynucleotides that minimize the value of Et given the desired melting temperature Td.
  • To illustrate the error calculation, an example nucleotide array experiment involving indicator polynucleotides for each exon and exon-exon junction of a transcript of the gene CD44 with the GenBank locus name XM030326, which contains 18 exons and 17 exon-exon junctions, is used. One indicator polynucleotide selection technique might select indicator polynucleotides with a length of 20 bases. Each indicator polynucleotide for an exon is selected to hybridize to the center of the exon, and each indicator polynucleotide for an exon-exon junction is selected to hybridize to 10 bases on each side of the exon-exon junction. The selected indicator polynucleotides are presented in the following table:
    TABLE 1
    SEQ ID NO Junction/Exon Melting Temp ° C. Sequence
    SEQ ID NO:1 E1 62.030003 cgcgcccagggatcctccag
    SEQ ID NO:2 J1-2 22.0 gcgcagatcgatttgaatat
    SEQ ID NO:3 E2 59.980003 ggaggccgctgacctctgca
    SEQ ID NO:4 J2-3 30.0 agacctgcaggtatgggttc
    SEQ ID NO:5 E3 53.83 tgcagcaaacaacacagggg
    SEQ ID NO:6 J3-4 32.0 aatgcttcagctccacctga
    SEQ ID NO:7 E4 53.83 agtcacagacctgcccaatg
    SEQ ID NO:8 J4-5 24.0 attaccataactattgttaa
    SEQ ID NO:9 E5 55.880005 gctcctccagtgaaaggagc
    SEQ ID NO:10 J5-6 28.0 cctgctaccactttgatgag
    SEQ ID NO:11 E6 51.780003 cctgggattggttttcatgg
    SEQ ID NO:12 J6-7 30.0 caaatggctggtacgtcttc
    SEQ ID NO:13 E7 49.730003 gatgaaagagacagacacct
    SEQ ID NO:14 J7-8 28.0 tccagcaccatttcaaccac
    SEQ ID NO:15 E8 55.880005 tggacccagtggaacccaag
    SEQ ID NO:16 J8-9 28.0 aggatgactgatgtagacag
    SEQ ID NO:17 E9 53.83 aagcacaccctcccctcatt
    SEQ ID NO:18 J9-10 32.0 acaagcacaatccaggcaac
    SEQ ID NO:19 E10 51.780003 ggtttggcaacagatggcat
    SEQ ID NO:20 J10-11 34.0 gggacagctgcagcctcagc
    SEQ ID NO:21 E11 49.730003 gacagttcctggactgattt
    SEQ ID NO:22 J11-12 28.0 agaaggatggatatggactc
    SEQ ID NO:23 E12 47.68 aatccaaacacaggtttggt
    SEQ ID NO:24 J12-13 28.0 atgacaacgcagcagagtaa
    SEQ ID NO:25 E13 47.68 gaaggcttggaagaagataa
    SEQ ID NO:26 J13-14 26.0 acatcaagcaataggaatga
    SEQ ID NO:27 E14 51.780003 acgaaggaaagcaggacctt
    SEQ ID NO:28 J14-15 30.0 tccttatcaggagaccaaga
    SEQ ID NO:29 E15 57.930004 cagtggggggtcccatacca
    SEQ ID NO:30 J15-16 30.0 gaatcagatggacactcaca
    SEQ ID NO:31 E16 53.83 ggagcaaacacaacctctgg
    SEQ ID NO:32 J16-17 28.0 caaattccagaatggctgat
    SEQ ID NO:33 E17 49.730003 ccttggctttgattcttgca
    SEQ ID NO:34 J17-18 34.0 gtcgaagaaggtgtgggcag
    SEQ ID NO:35 E18 53.83 tcgttccagttcccacttgg
  • The NCBI locus name and version for the genomic sequence containing the CD44 gene is NT024229.8. The NCBI locus name and version for the mRNA sequence of the CD44 transcript is XM030326.3. The identifiers E1, E2, E3, and etc. identify indicator polynucleotides for exon 1, exon 2, exon 3, and etc. The identifiers J1-2, J2-3, and etc. identify indicator polynucleotides for the exon-exon junction between exon 1 and exon 2, the exon-exon junction between exon 2 and exon 3, and etc. The melting temperatures are theoretical melting temperatures of one exon portion of the indicator polynucleotide, calculated according to the following equation:
    T m=64.9° C.+41° C.*(GC−16.4)/L   (5)
  • where L is the length of the target polynucleotide and GC is the GC content. One skilled in the art will appreciate the theoretical melting temperature can be calculated using various well-known equations. The calculated melting temperature varies from a low of 22° C. to a high of 62.03° C. in this example. This wide range of melting temperatures will lead to substantial variation in the number of polynucleotides that hybridize to instances of a given indicator polynucleotides in an experiment with fixed hybridization and washing temperatures. For example, in an experiment with a sample containing CD44 using a standard protocol with a hybridization temperature of 52° C. and a washing temperature of 52° C., the indicator polynucleotides with melting temperatures under 52° C. will form and retain hybridization products less frequently than those with melting temperatures above 52° C. In general, indicator polynucleotides with low calculated melting temperatures may not bind to their target exons or exon-exon junctions with any measurable strength above a background level. The error with a target temperature of 52° C. is calculated using equation 2 in the following:
    E t 2=(52−62.03)2+(52−22)2+ . . . +(52−53.83)2=(97.46)2
    Modifying Indicator Polynucleotides to Reduce Errors in Melting Temperatures
  • The optimization technique can optimize an indicator polynucleotide prior to running the experiment. The optimization technique may optimize indicator polynucleotides by shifting the location of the indicator polynucleotides slightly upstream or downstream within their respective RNAs. For example, the optimization technique can select indicator polynucleotides for exons from any base range within the exon that the indicator polynucleotide identifies, using any selection criteria, such as GC content. Alternatively, the optimization technique can optimize indicator polynucleotides by varying their lengths. For example, rather than selecting only indicator polynucleotides with a length of 20 bases, the optimization technique may select indicator polynucleotides of varying lengths to reduce the error measure for each indicator polynucleotide. These various optimizations may be used alone or in conjunction with other indicator polynucleotide selection, analytical correction, or other optimizations. When varying the length of the indicator polynucleotides for the same CD44 transcript, without using other indicator polynucleotide selection or optimizations, the resulting indicator polynucleotide are shown in the following:
    TABLE 2
    SEQ ID NO Junction/Exon Melting Temp ° C. Sequence
    SEQ ID NO:36 E1 51.062504 ccca atcctcca
    SEQ ID NO:37 J1-2 52.258335 cgcagatcgatttgaatataacct
    SEQ ID NO:38 E2 51.062504 aggccgctgacctctg
    SEQ ID NO:39 J2-3 53.24737 gacctgcaggtatgggttc
    SEQ ID NO:40 E3 51.089478 tgcagcaaacaacacaggg
    SEQ ID NO:41 J3-4 51.089478 aatgcttcagctccacctg
    SEQ ID NO:42 E4 51.089478 agtcacagacctgcccaat
    SEQ ID NO:43 J4-5 51.653847 caattaccataactattgttaaccgt
    SEQ ID NO:44 E5 53.24737 ctcctccagtgaaaggagc
    SEQ ID NO:45 J5-6 51.780003 cctgctaccactttgatgag
    SEQ ID NO:46 E6 52.97273 cctgggattggttttcatggtt
    SEQ ID NO:47 J6-7 51.780003 caaatggctggtacgtcttc
    SEQ ID NO:48 E7 51.109093 aagatgaaagagacagacacct
    SEQ ID NO:49 J7-8 51.780003 ccagcaccatttcaaccaca
    SEQ ID NO:50 E8 52.600002 ggacccagtggaacccaa
    SEQ ID NO:51 J8-9 51.7087 aaggatgactgatgtagacagaa
    SEQ ID NO:52 E9 51.876472 gcacaccctcccctcat
    SEQ ID NO:53 J9-10 52.404762 tacaagcacaatccaggcaac
    SEQ ID NO:54 E10 51.780003 ggtttggcaacagatggcat
    SEQ ID NO:55 J10-11 51.876472 ggacagctgcagcctca
    SEQ ID NO:56 E11 52.404762 gacagttcctggactgatttc
    SEQ ID NO:57 J11-12 52.97273 aagaaggatggatatggactcc
    SEQ ID NO:58 E12 51.109093 caaatccaaacacaggtttggt
    SEQ ID NO:59 J12-13 51.7087 aatgacaacgcagcagagtaatt
    SEQ ID NO:60 E13 51.7087 gaaggcttggaagaagataaaga
    SEQ ID NO:61 J13-14 51.7087 gacatcaagcaataggaatgatg
    SEQ ID NO:62 E14 51.089478 acgaaggaaagcaggacct
    SEQ ID NO:63 J14-15 50.452385 ttccttatcaggagaccaaga
    SEQ ID NO:64 E15 51.062504 tggggggtcccatacc
    SEQ ID NO:65 J15-16 51.109093 tgaatcagatggacactcacat
    SEQ ID NO:66 E16 51.089478 ggagcaaacacaacctctg
    SEQ ID NO:67 J16-17 52.97273 ccaaattccagaatggctgatc
    SEQ ID NO:68 E17 52.404762 ccttggctttgattcttgcag
    SEQ ID NO:69 J17-18 52.600002 gtcgaagaaggtgtgggc
    SEQ ID NO:70 E18 51.089478 tcgttccagttcccacttg
  • Since the calculated polynucleotide melting temperatures have a small range, from 50.45° C. to 52.97° C. (rather than 22° C. to 62.03° C.), the error measure Et of 4.51 (rather than 97.46) is also small. This varying of the lengths of the indicator polynucleotides has eliminated over 95% of the error encountered when the indicator polynucleotides were selected as shown in Table 1.
  • FIG. 1 is a flow diagram illustrating the overall process of selecting indicator polynucleotides to minimize the errors between the actual melting temperatures and the desired melting temperature in one embodiment. In block 101, the technique selects an initial set of indicator polynucleotides. In block 102, the technique inputs the desired melting temperature of the indicator polynucleotides. In blocks 103-105, the technique modifies each indicator polynucleotide to minimize its error. In block 103, the technique selects the next indicator polynucleotide. In decision block 104, if all the indicator polynucleotides have already been selected, then the technique completes, else the technique continues at block 105. In decision block 105, if the error between actual melting temperature of the selected indicator polynucleotide and the desired melting temperature is acceptable, then the technique selects the next indicator polynucleotide, else the technique continues at block 106. In block 106, the technique modifies the selected indicator polynucleotide using one or more of the described techniques (e.g., adjusting the length of the indicator polynucleotide or moving the indicator polynucleotide upstream or downstream) and then continues at a block 105.
  • One skilled in the art will recognize that the error Et may be further reduced in a variety of ways, such as by introducing molecules other than the bases A, C, G, or T with different binding characteristics. Such bases may be appended, prepended, inserted, or selectively substituted within the indicator polynucleotides.
  • CD44 is known to have several splice variants. For example, the transcript used above contains several exons not present in other splice forms of CD44. In particular, J6-7 does not exist in some species of CD44. Instead, E6 joins with a later exon E7′, yielding J6-7′. The RNA transcript containing the J6-7 is referred to as R1, and the RNA transcript containing J6-7′ is referred to as R2.
  • When using indicator polynucleotides to identify exon-exon junctions, binding may be less specific than desired if polynucleotides bind to one or the other half of an indicator polynucleotide. For example, if J6-7 is not present in a given sample, but E6 is present (because a different splice form of the gene is present in that sample), then an indicator polynucleotide for J6-7 may hybridize to E6 even though E6 is not joined to E7 in the splice variant in the sample. The hybridization, however, will likely be weaker than if a splice variant containing J6-7 was present. The expression levels may be measured as
    H(E6)=1069
    H(J6-7)=388
    where H(E6) is the measured expression level of E6 in the experiment and H(J6-7) is the measured expression level of J6-7. These measured expression may represent the following scenarios:
      • 1. R1 is present but R2 is not present.
      • 2. R1 and R2 are both present.
      • 3. Neither R1 nor R2 is present, but another splice variant R3is present. R3 contains both E6 and E7, but not J6-7, because some alternate splicing event or events occurs between E6 and E7.
  • Techniques described in U.S. patent application Ser. No. 10/146,720, entitled “Method and System for Identifying Splice Variants of a Gene,” can be used to differentiate these scenarios. Those techniques assign an expected expression level to J6-7 in the presence of R1, in the presence of R2, and in the presence of R3. For example, if there are indicator polynucleotides for E6, E7, and J6-7, then a matrix M with a column for each expected splice variant (e.g., R1, R2 and R3) and a row for each indicator polynucleotide (e.g., E6, E7, and J6-7) is created. The values in the matrix correspond to the expected expression level for the target polynucleotides. When the partial expression levels are not expected, the matrix might look like the following: M R 1 R 2 R 3 M = 1 1 1 1 0 0 1 0 1 E 6 J 6 - 7 E 7
  • If the indicator polynucleotide for J6-7, however, weakly binds in the presence of a different splice site, J6-7′, a correction can be applied. The values in the correction matrix can be calculated or empirically derived. The values can be empirically derived by performing a hybridization experiment containing J6-7′ but not J6-7. The correction matrix may be derived using one or more samples containing antisense polynucleotides. A sample could include antisense polynucleotides for J6 or J7 or both. (“J6” refers to the portion of an indicator polynucleotide for a J6-X junction that is used to identify the E6 portion of the junction.) For example, an antisense polynucleotide for J6 might contain the complementary polynucleotide for J6. Alternatively, the antisense polynucleotide might contain the complementary polynucleotide for J6 appended to a sequence of some additional number of bases, perhaps chosen randomly. In yet another scenario, the antisense polynucleotide might contain J6 with J7 prepended. After the hybridization experiments, the following expression values may result:
    H(J6-7|J6)=556
    H(J6-7|J7)=310
    H(J6-7|J6-7)=1544
    H(J6-7|J6, J7)=756
    where H(J6-7|J6) is the empirically derived expression level of the indicator polynucleotide for J6-7 in the presence of a sample containing antisense polynucleotides for J6, H(J6-7|J7) is the expression level of J6-7 in the presence of a sample containing antisense polynucleotides for J7, H(J6-7|J6-7) is the ordinary expression level of J6-7 in the presence of antisense polynucleotides for J6-7, and H(J6-7|J6, J7) is the expression level of J6-7 in the presence of separate antisense polynucleotides for J6 and J7. The expression values are not independent and are preferably measured in separate hybridization experiments. If more than one expression level is measured in the same experiment, the individual values can be solved using a system of linear equations, a least squares equation, or another deconvolution method.
  • Once the expression levels have been determined either empirically or theoretically, the values in the matrix M could be determined using an equation such as:
    M i,j =H(P i |R j)/H(P i)   (6)
    where Mi,j is a coefficient matrix, Pi is an indicator polynucleotide that identifies a subsequence of RNA transcript Rj, H(Pi|Rj) is the expression level of indicator polynucleotide Pi given that RNA Rj is expressed, and H(Pi) is the expression level of the hybridization product of indicator polynucleotide i. The solution to this equation is:
    M 2,1 =H(J6-7|J6-7)/H(J6-7|J6-7)=1544/1544−1=1
    M 2,2 =H(J6-7|J6)/H(J6-7|J6-7)=556/1544=0.36
    M 2,3 =H(J6-7|J6,J7)/H(J6-7|J6-7)=756/1544=0.49
  • In this example, H(J6-7|J6-7) is the expression of the indicator polynucleotide for J6-7 given RNA containing J6-7 is present. The remaining matrix elements all have a value of 1, for the same reason as M2,1. The resulting matrix M is: M R 1 R 2 R 3 M = 1 1 1 1 0.36 0.49 1 0 1 E 6 J 6 - 7 E 7
    The value 0.36 indicates that the indicator polynucleotide for J6-7 will yield a relative expression level of 0.36 times the full value if R2 is present, and the other two splice variants are not present. The expression level is non-zero in this case because the indicator polynucleotide for J6-7 will hybridize weakly in the presence of E6 even if J6-7 is not present. The value 0.49 indicates that the indicator polynucleotide for J6-7 will yield a relative expression level of 0.49 times the full value if R3 is present and the other two splice variants are not present. The value for J6-7 in R3 is larger than the corresponding value in R2 because the indicator polynucleotide will hybridize weakly to both E6 and E7 rather than only to E6.
    Modifying a Junction Indicator Polynucleotide to Balance Its Melting Temperature
  • The indicator polynucleotide for J6-7 consists of a portion J6 that identifies the 3′ end of E6 as well as a portion J7 that identifies the 5′ end of E7. Each of these portions has its own melting temperature. In other words, the indicator polynucleotide for J6-7 will hybridize to E6 based on the melting temperature of J6 even if J6-7 is not present in the sample. Likewise, the indicator polynucleotide will hybridize to E7 based on the melting temperature of J7 even if J6-7 is not present in the sample. In one embodiment, the optimization technique balances the melting temperature of each exon portion of a junction indicator polynucleotide.
  • A full set of exon-exon junction indicator polynucleotides with a length of 30 bases for CD44 selected to have 15 bases for each exon is shown in the following:
    TABLE 3
    Junction/ Melting Left Melting Right Melting
    SEQ ID No Exon Temp ° C. Temp ° C. Temp ° C. Sequence
    SEQ ID J1-2 61.620003 50.140003 28.273338 gcctggcgcagatcgatttgaatataacct
    NO: 71
    SEQ ID J2-3 60.253334 39.20667 36.473335 atttgagacctgcaggtatgggttcataga
    NO: 72
    SEQ ID J3-4 62.986668 39.20667 41.940002 gcttcaatgcttcagctccacctgaagaag
    NO: 73
    SEQ ID J4-5 57.520004 33.74 36.473335 gaccaattaccataactattgttaaccgtg
    NO: 74
    SEQ ID J5-6 61.620003 41.940002 36.473335 gaatccctgctaccactttgatgagcacta
    NO: 75
    SEQ ID J6-7 58.88667 39.20667 33.74 caacacaaatggctggtacgtcttcaaata
    NO: 76
    SEQ ID J7-8 61.620003 39.20667 39.20667 ttatctccagcaccatttcaaccacaccac
    NO: 77
    SEQ ID J8-9 60.253334 41.940002 33.74 ccacaaggatgactgatgtagacagaaatg
    NO: 78
    SEQ ID J9-10 60.253334 33.74 41.940002 attctacaagcacaatccaggcaactccta
    NO: 79
    SEQ ID J10-11 65.72 44.673336 41.940002 caacagggacagctgcagcctcagctcata
    NO: 80
    SEQ ID J11-12 62.986668 41.940002 39.20667 caggaagaaggatggatatggactccagtc
    NO: 81
    SEQ ID J12-13 58.88667 36.473335 36.473335 tttcaatgacaacgcagcagagtaattctc
    NO: 82
    SEQ ID J13-14 58.88667 39.20667 33.74 ctctgacatcaagcaataggaatgatgtca
    NO: 83
    SEQ ID J14-15 60.253334 36.473335 39.20667 atcgttccttatcaggagaccaagacacat
    NO: 84
    SEQ ID J15-16 61.620003 36.473335 41.940002 gatctgaatcagatggacactcacatggga
    NO: 85
    SEQ ID J16-17 61.620003 41.940002 36.473335 caccccaaattccagaatggctgatcatct
    NO: 86
    SEQ ID J17-18 62.986668 39.20667 41.940002 caacagtcgaagaaggtgtgggcagaagaa
    NO: 87

    The melting temperature is the calculated melting temperature of the complete indicator polynucleotide, the left melting temperature is the calculated melting temperature of the first 15 bases of the indicator polynucleotide which detect the 3′ end of the first exon in each junction, and the right melting temperature is the calculated melting temperature of the last 15 bases of the indicator polynucleotide which detect the 5′ end of the second exon in each junction. The variation between the two sides of a given indicator polynucleotide may be considerable; the difference between the left and right melting temperature for the same indicator polynucleotide is as large as 21.87° C. for J1-2.
  • The temperature difference in J6-7 is approximately 5.5° C. The expected result of the difference is that the indicator polynucleotide will yield a larger expression value if E6 is present without J6-7 than if E7 is present without J6-7. A similar effect will be observed to varying degrees for all of the indicator polynucleotides. In one embodiment, the optimization technique corrects for these effects using the linear equations presented above. For example, different values for a transcript containing E6 but not E7 than for a transcript containing E7 but not E6 may be used. The corrected matrix might look like this: M C R 1 R 2 R 3 M c = 1.00 1.00 0.00 1.00 0.41 0.29 1.00 0.00 1.00 E 6 J 6 - 7 J 7
    where R2 is a transcript containing E6 but not E7 and R3 is a transcript containing E7 but not E6. However, it would be desirable to minimize the need to correct experimental results in this way, since it is generally desirable to minimize the number of experimental parameters that vary in the same experiment. The optimization technique minimizes or eliminates the need for this correction by balancing the melting temperature on each side of the exon-exon junction, so that the melting temperatures of indicator polynucleotide portions J6 and J7 are close to equal.
  • An optimization equation for error from imbalanced melting temperature using Euclidean distance can be written as:
    E x 2=(T ia −T ib)2   (7)
    where Ex is the error from imbalance in melting temperature, Tia is the calculated or empirical melting temperature of the portion of the indicator polynucleotide which identifies the 3′ end of the first exon, and Tib is the calculated melting temperature of the portion of the indicator polynucleotide which identifies the 5′ end of the second exon. If the indicator polynucleotide does not identify an exon-exon junction, the error is zero. The total error in the experiment then is given by:
    E xt 2 =E x1 2 +E x2 2 + . . . +E xn 2   (8)
    where Ext is the total error from multiple indicator polynucleotides as a result of temperature imbalance in indicator polynucleotides that identify exon-exon junctions. One skilled in the art will appreciate that error metrics other than Euclidean distance may be used.
  • In one embodiment, the optimization technique considers both temperature balancing in exon-exon junction indicator polynucleotides and total indicator polynucleotide melting temperature, which can be represented by the following equation:
    E jt =k 1 E+k 2 E x   (9)
    where Ejt is the joint error measure, E is given by equation 1, Ex is given by equation 7, and k1 and k2 are constants. The total joint error measure can be represented by the following equation:
    E jt =E j1 +E j2 + . . . +E jn   (10)
    where Ejt is the total error from both temperature imbalance in exon-exon junction indicator polynucleotides and each Eji is the error for each individual indicator polynucleotide i calculated using equation 9. One skilled in the art will appreciate that error metrics other than Euclidea distance can be used and that equations 7-10 can be generalized as equations 3 and 4 were generalized.
  • The exon-exon junction indicator polynucleotides selected from CD44 according to equations 7-10, using a desired total melting temperature Td=60° C. and k1=k2=1.0 are shown in the following:
    TABLE 4
    Junction/ Melting Left Melting Right Melting
    SEQ ID No Exon Temp ° C. Temp ° C. Temp ° C. Sequence
    SEQ ID J1-2 59.921432 38.0 37.405884 ggcgcagatcgatttgaatataacctgc
    NO:88
    SEQ ID J2-3 59.921432 38.0 38.25 tgagacctgcaggtatgggttcatagaa
    NO:89
    SEQ ID J3-4 61.255558 39.20667 38.0 gcttcaatgcttcagctccacctgaag
    NO:90
    SEQ ID J4-5 59.59412 39.81765 39.81765 tggaccaattaccataactattgttaaccgtgat
    NO:91
    SEQ ID J5-6 59.737038 37.37143 38.0 aatccctgctaccactttgatgagcac
    NO:92
    SEQ ID J6-7 60.40323 39.20667 38.25 caacacaaatggctggtacgtcttcaaatac
    NO:93
    SEQ ID J7-8 59.737038 37.37143 38.0 tatctccagcaccatttcaaccacacc
    NO:94
    SEQ ID J8-9 60.253334 37.37143 38.25 cacaaggatgactgatgtagacagaaatgg
    NO:95
    SEQ ID J9-10 59.921432 38.25 38.0 cattctacaagcacaatccaggcaactc
    NO:96
    SEQ ID J10-11 59.980003 34.0 34.0 gggacagctgcagcctcagc
    NO:97
    SEQ ID J11-12 59.737038 37.37143 38.0 aggaagaaggatggatatggactccag
    NO:98
    SEQ ID J12-13 58.88667 36.473335 36.473335 tttcaatgacaacgcagcagagtaattctc
    NO:99
    SEQ ID J13-14 60.54375 39.20667 39.81765 ctctgacatcaagcaataggaatgatgtcaca
    NO:100
    SEQ ID J14-15 59.737038 38.0 37.37143 cgttccttatcaggagaccaagacaca
    NO:101
    SEQ ID J15-16 61.506897 40.8125 40.0 ggatctgaatcagatggacactcacatgg
    NO:102
    SEQ ID J16-17 60.093105 37.37143 36.473335 accccaaattccagaatggctgatcatct
    NO:103
    SEQ ID J17-18 59.324 38.0 38.0 acagtcgaagaaggtgtgggcagaa
    NO:104
  • Variations between the left melting temperature and right melting temperature values has decreased significantly; the maximum difference between left melting temperature and right melting temperature is now only approximately 0.95° C. The temperature balancing technique has eliminated over 95% of the variability in melting temperature between the two portions of each exon-exon junction indicator polynucleotide as compared to the indicator polynucleotide selection technique. The melting temperature of a fixed-length indicator polynucleotide can be balanced by decreasing the length of one exon's portion and increasing the length of the other exon's portion. For example, if the length of the indicator polynucleotide for a junction is 20 and the length of each portion is 10, then the length of one portion may be decreased to 8 and the length of the other portion might be increased to 12 to balance the melting temperature, keeping the overall length at 20. Corrections can be applied to experimental results, as described above, to further reduce the variability.
  • Correcting Analytically for Variations in Melting Temperature
  • In one embodiment, the optimization technique corrects for variations in polynucleotide melting temperatures during analysis of the experimental results.
  • This correction can be used whether or not an optimal set of indicator polynucleotides is selected as described above. The optimization technique adjusts the detected expression levels of the polynucleotides based on theoretical and desired melting temperatures. FIG. 2 is a flow diagram illustrating the overall process of analytically correcting for variations in melting temperatures in one embodiment. The steps of the processes illustrated by the flow diagrams may be controlled by, performed with the assistance of, or performed by a computer system. One skilled in the art will appreciate that various steps may be performed manually. In block 201, the technique selects the indicator polynucleotides that are to be used to identify target polynucleotides in a sample. In block 202, the technique performs the hybridization experiment, for example, using nucleotide array technology. In block 203, the technique receives the resulting expression levels from the experiment. In block 204, the technique calculates or inputs the melting temperature for each of the indicator polynucleotides. In block 205, the technique adjusts the expression levels based on the melting temperature for each of the indicator polynucleotides and temperature (e.g., hybridization temperature or wash temperature) at which the experiment was performed to give the final calculated expression levels for the experiment. One example analysis technique is described in U.S. patent application Ser. No. 10,146,720, filed on May 14, 2002 and entitled “Method and System for Identifying Splice Variants of a Gene,” which is hereby incorporated by reference. That splice variants analysis calculates the expression levels according to the following equation:
    S=MH   (11)
    where S is a solution matrix of expression levels with a row for each expected RNA transcript and a column for each experiment, M is a matrix of coefficients in which each column corresponds to an expected RNA transcript and each row corresponds to an indicator polynucleotide in the experiment (each coefficient indicates the relative expected expression level of the indicator polynucleotide for the expected RNA transcript), and H is a matrix in which each of the columns corresponds to expression values derived from an expression array experiment. Because of experimental noise, an exact solution to this equation may not exist. The splice variants analysis can find an approximation using a variety of techniques such as a least squares regression using the following equation:
    S=(MM T)−1 M T H  (12)
    where MT transpose of M. The values in the coefficient matrix M can be represented by the following equation:
    M i,j =L(P i |R j)   (13)
    where Mi,j is the matrix element in the ith row and jth column and L(Pi|Rj) defines a coefficient for indicator polynucleotide P (in the ith row of M) given that the expected RNA transcript R (in the jth column of M) is present in a sample.
  • If all indicator polynucleotides that identify subsequences of R are expected to be expressed at an identical level when R is present in the sample, and all indicator polynucleotides that do not identify subsequences of R are expected not to be expressed at all, matrix M might consist entirely of zeros and ones. The matrix M for two splice variants of CD44, R1 and R2, is represented by the following: R 1 R 2 M = 1 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 1 0 1 0 1 0 1 0 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 E 1 E 2 E 3 E 4 E 5 E 6 J 6 - 7 E 7 J 7 - 8 E 8 J 8 - 9 E 9 J 6 - 10 J 9 - 10 E 10 E 11 E 12 E 13 E 14 E 15 E 16 E 17 E 18
  • The value of 0 indicates the expected expression level will be zero if the target polynucleotide (e.g., J6-10) is not present in the sample. The uniform value of 1 indicates the expected expression levels of all other indicator polynucleotides will be equal if the expected RNA transcript is present in the sample. The indicator polynucleotides, however, may identify their target polynucleotides at varying expression levels because of variations in the melting temperature of the indicator polynucleotides.
  • In one embodiment, the optimization technique adjusts the detected expression levels to account for the variations in melting temperatures. Continuing with the CD44 gene example, the calculated melting temperatures are used to scale the expected expression levels in matrix M. If the expected expression levels varied linearly with respect to temperature, then the expected expression levels can be adjusted according to the following equation:
    M i,j =T i /T d   (14)
    where Mi,j element in the ith row and jth column of the matrix M, Ti is the expected melting temperature of the indicator polynucleotide corresponding to row i, and Td is the desired melting temperature for use in the experiment. If the melting temperature is 62.03 and the desired melting temperature is 52, then the adjusted expression level would be 1.19 (i.e., 62.02/52).
  • Alternatively, the optimization technique performs the correction by adjusting the detected expression levels of matrix H, rather than adjusting the coefficients of matrix M. If the detected expression level varied linearly with respect to temperature, the detected expression levels can be adjusted according to the following equation:
    H′ i,j =H i,j T d /T i   (15)
    where Hi,j is the detected expression level for indicator polynucleotide i in experiment j, H′i,j is the corrected expression level, Ti is the expected melting temperature of the indicator polynucleotide corresponding to row i, and Td is the desired melting temperature. If the melting temperature is 62.03, the desired melting temperature is 52, and the detected expression level is 11,869, then the adjusted expression level is 9950 (i.e., 11,869*52/62.03).
  • Since expected expression levels will likely vary with respect to temperature according to an equation that is more complex than a linear equation, the optimization technique in one embodiment may apply a correction based on one or more empirical hybridization experiments. One such experiment creates a sample consisting of synthesized polynucleotides to bind to indicator polynucleotides on a nucleotide array. The optimization technique then calculates the expected expression levels of matrix M according to the following equation:
    Mi,j=k Hi   (16)
    where Mi,j is the element in the ith row and jth column of the matrix M, Hi is an empirically derived expression level for the indicator polynucleotide i from a hybridization experiment, and k is a constant. For example, if the expression level of an indicator polynucleotide is 1481 and the average expression level from the experiment is 1208, then k is 1/1208 resulting in a corrected expected expression level of 1.23 (e.g., (1/1208)*1481).
  • The optimization technique can also correct for 3′ bias, which occurs in some methods of RNA amplification, such as T7 amplification. In one embodiment, the optimization technique calculates the corrected expression level according to the following equation:
    M i,j =f(H i,b)   (17)
    where f is a function such as a linear or nonlinear equation and Hi,b is the expected expression level for an indicator polynucleotide i which identifies a target polynucleotide located b bases from the 3′ end of the RNA transcript in column j. For example, if the expression level for polynucleotides drops off linearly measured by the number of bases from the 3′ end of the RNA transcript, function f can be represented by the following equation:
    f(H i,b)=k 1 −k 2 b   (18)
    where k1 is the maximum value at the 3′ end of the polynucleotide and k2 is the rate at which the expression level drops for each nucleotide base from the 3′ end. If k1 is 1.00, k2 is 1.2E-2, and the target polynucleotide is located 1,303 bases from the 3′ end of the RNA transcript, then the value of function f is represented by the following equation:
    M i,j =f(H i, 1303)=1.00−1.2E-4*1303=0.84364
    Alternatively, the optimization technique can apply the 3′ bias correction to the empirically derived expression levels of matrix H, rather than matrix M, resulting in the following equation:
    H′ 1,1 =H i,j f(H i,b)−1=11,869*(0.84364)−1=14,069
  • The optimization technique can use more complex functions when the expression level varies nonlinearly with respect to the distance from the 3′ end. For example, the expression level might drop precipitously when b exceeds some value. The optimization technique can use a nonlinear equation to represent such a drop.
  • The optimization technique can apply multiple corrections to the same matrix as indicated by the following equation:
    M′ i,j =M i,j *C 1 i,j *C 2 i,j * . . . *C n i,j   (19)
    where M′ is the corrected matrix, Mi,j is a starting matrix element value, and the various Ci,j are element-by-element multiplicative corrections such as the 3′ bias correction described above. The optimization technique can represent the correction more generally by the following equation:
    M′ i,j =f(M i,j , C 1 i,j , C 2 i,j , . . . , C n i,j)   (20)
    where the Ci,js are correction factors that may be applied using element-by-element corrections, such as multiplication, addition, or subtraction. The optimization technique can alternatively apply the multiple correction factors to matrix H, rather than matrix M according to the following equations:
    H′ i,j =H i,j*(C 1 i,j)−1*(C 2 i,j)−1* . . . *(C n i,j)−1  (21)
    H′ i,j =f(H i,j , C 1 i,j , C 2 i,j , . . . , C n i,j)   (22)
    where f is a function that applies each individual correction to the empirically derived expression level.
    Correcting for Presence of Homologous Polynucleotides
  • In one embodiment, the optimization technique corrects for the presence of homologous polynucleotides in a sample. In particular, an indicator polynucleotide identifies a target polynucleotide in an RNA transcript, but it may also identify, albeit less strongly, a homologue of the target polynucleotide in a different RNA transcript. The RNA transcripts may differ by only a few bases. The optimization technique can correct for a homologue in the sample by adding a column to matrix M for the homologue. The column might have a value only in row i if no other indicator polynucleotide in the experiment identifies a subsequence of the different RNA transcript. The solution can be found in various ways, such as using a system of linear equations or a least squares algorithm as described above.
  • Alternatively, the optimization technique may determine the contribution to the expression level of the indicator polynucleotide resulting from the homologue if the expression level of the homologue by itself is known. Such determination would not have to rely on a single indicator polynucleotide to identify the expression level of both the target polynucleotide and the homologue. The optimization technique can determine the expression level of the homologue by selecting one or more “control indicator polynucleotides” specific to the homologue. FIG. 3 is a flow diagram illustrating the overall process of correcting for hybridization of an indicator polynucleotide with a homologue of the target polynucleotide in one embodiment. In block 301, the technique selects the indicator polynucleotide. In block 302, the technique selects a control polynucleotide. In block 303, the technique performs the experiment using the indicator polynucleotide and a control indicator polynucleotide. In block 304, the technique retrieves the expression levels from the experiment. In block 305, the technique adjusts the expression levels based on the characteristics of the control indicator polynucleotide. The optimization techniques can identify control indicator polynucleotides by selecting a region of the 3′ untranslated of the homologue, confirming that it has no homologues by performing a similarity search (such as a BLAST search) against a database of known sequences, and designing control indicator polynucleotide to identify that region.
  • The optimization technique includes this control indicator polynucleotide in the experiment to correct the original indicator polynucleotide that may be weakly identifying the homologue instead of or in addition to the target polynucleotide.
  • The correction may be performed according to the following equation:
    H(P i)=H(N i)+kH(N′ i)  (23)
    where H(Pi) is the expression level of indicator polynucleotide Pi, H(Ni) is the detected expression level of the target polynucleotide Ni, k is a constant, and H(N′i) is the detected expression level of the homologous polynucleotide N′i. The constant k accounts for differences between the target polynucleotide and its homologue. In such a case, the contribution of the homologous polynucleotide to the expression level measured for an indicator polynucleotide Pi will be less than its independent expression level as measured by the control indicator polynucleotide. For example, if it is expected that the homologue will bind at ⅔ the proportion of its actual expression level, the value of k would be ⅔. The value of k may be determined empirically by performing hybridizations with the homologous polynucleotide and the indicator polynucleotide whose expression level is the numerator of k and with the homologous polynucleotide and the control indicator polynucleotide whose expression level is the denominator of k. Alternatively it may be calculated theoretically using an equation such as the following equation:
    H(P i |N′ i)=f(P i , N′ i)   (24)
    where H(Pi|N′i) is the empirically derived expression level of polynucleotide Pi when hybridized to a sample containing polynucleotide N′i, and f(Pi, N′i) is a function of the two polynucleotides that are binding. The function f may take into consideration various factors such as the number of matches, the individual melting temperatures of the polynucleotides assuming perfect matches, base stacking, salt concentration, GC content, the precise pairing of mismatched bases, number of hydrogen bonds, magnesium concentration, primer concentration, length of perfectly matching regions, melting temperature of perfectly matching regions, distance of mismatches from the ends of the polynucleotides, and so on.
  • In the following example, the optimization technique corrects for an indicator polynucleotide that identifies a target polynucleotide and its homologue. The control indicator polynucleotide is used to determine the independent expression level of the RNA containing the homologue. The optimization technique calculates the value of the constant k as 0.723. When the experiment is run with the indicator polynucleotide and the control indicator polynucleotide, the resulting expression levels are 36,366 and 15,695, respectively. The optimization technique calculates the independent expression level of the target polynucleotide as follows:
    36366=H(N i)+0.723*15695
    H(N i)=36366−0.723*15695=25018
    Alternatively, the optimization technique can apply the homologue correction as a correction matrix to matrix H, rather than matrix M.
  • From the foregoing, it will be appreciated that specific embodiments of the invention have been described herein for purposes of illustration, but that various modifications may be made without deviating from the spirit and scope of the invention. For example, one skilled in the art will recognize the various ways in which the temperature balancing method and other indicator polynucleotide selection, optimization and correction techniques described here can be combined with existing methods. For example, the indicator polynucleotide selection techniques may be implemented or executed by means of a computer. Accordingly, the invention is not limited except as by the appended claims.

Claims (36)

1-22. (canceled)
23. A nucleotide array, comprising: an exon-exon junction indicator polynucleotide, comprised of a first portion that indicates a 5′ exon of an exon-exon junction and a second portion that indicates a 3′ exon of an exon-exon junction, the first portion and the second portion each having a length, wherein the length of the first portion is equal to the length of the second portion.
24. The array of claim 23, comprised of a plurality of said exon-exon junction indicator polynucleotides.
25. The array of claim 24, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of a splice variant of a gene.
26. The array of claim 24, wherein the plurality comprises indicator polynucleotides for exon-exon junctions of multiple splice variants of a gene.
27. The array of claim 24, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of multiple splice variants of a gene.
28. The array of claim 24, wherein the plurality comprises at least about 17 indicator polynucleotides.
29. The array of claim 24, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is the same.
30. The array of claim 23, wherein the array further comprises a plurality of exon indicator polynucleotides.
31. A nucleotide array, comprising: an exon-exon junction indicator polynucleotide comprised of a first portion that indicates a 5′ exon of an exon-exon junction and a second portion that indicates a 3′ exon of an exon-exon junction, the first portion and the second portion each having a length, wherein the length of the first portion is not equal to the length of the second portion.
32. The array of claim 31, comprised of a plurality of said exon-exon junction indicator polynucleotides.
33. The array of claim 32, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of a splice variant of a gene.
34. The array of claim 32, wherein the plurality comprises indicator polynucleotides for exon-exon junctions of multiple splice variants of a gene.
35. The array of claim 32, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of multiple splice variants of a gene.
36. The array of claim 32, wherein the plurality comprises at least about 17 indicator polynucleotides.
37. The array of claim 32, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is the same.
38. The array of claim 32, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is not the same.
39. A nucleotide array, comprising: an exon-exon junction indicator polynucleotide comprised of a first portion that indicates a 5′ exon of an exon-exon junction and a second portion that indicates a 3′ exon of an exon-exon junction, wherein the first portion has a melting temperature and the second portion has a melting temperature, and wherein the melting temperature of the first portion approximately equals the melting temperature of the second portion.
40. The array of claim 39, wherein the first portion has a length and the second portion has a length, and wherein the length of the first portion is equal to the length of the second portion.
41. The array of claim 39, wherein the first portion has a length and the second portion has a length, and wherein the length of the first portion is not equal to the length of the second portion.
42. The array of claim 39, comprised of a plurality of said exon-exon indicator polynucleotides.
43. The array of claim 40, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of a splice variant of a gene.
44. The array of claim 40, wherein the plurality comprises indicator polynucleotides for exon-exon junctions of multiple splice variants of a gene.
45. The array of claim 40, wherein the plurality comprises indicator polynucleotides for all exon-exon junctions of multiple splice variants of a gene.
46. The array of claim 40, wherein the plurality comprises at least about 17 indicator polynucleotides.
47. The array of claim 40, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is the same.
48. The array of claim 40, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is not the same.
49. The array of claim 43, wherein for each indicator polynucleotide for the exon-exon junctions of the splice variant, the melting temperature of the first portion and the melting temperature of the second portion differ by about 0.95 degrees Celsius or less.
50. A nucleotide array, comprising: a plurality of exon indicator polynucleotides for exons of a splice variant of a gene comprised of a plurality of exons.
51. The array of claim 50, further comprising a plurality of exon indicator polynucleotides for exons of multiple splice variants of the gene.
52. The array of claim 50, further comprising a plurality of exon indicator polynucleotides for all exons of multiple splice variants of the gene.
53. The array of claim 50, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is the same.
54. The array of claim 50, wherein the gene is comprised of a plurality of at least about 18 exons.
55. The array of claim 50, wherein each indicator polynucleotide has a length, and wherein the length of each indicator polynucleotide is not the same.
56. The array of claim 55, wherein each indicator polynucleotide has a melting temperature, and wherein the melting temperatures of each indicator polynucleotides is approximately the same.
57. The array of claim 55, wherein each indicator polynucleotide has a melting temperature, and wherein the melting temperatures of the indicator polynucleotides differ by about 2.52 degrees Celsius or less.
US11/361,627 2001-07-25 2006-02-24 Microarray device with optimized indicator polynucleotides Abandoned US20060199208A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/361,627 US20060199208A1 (en) 2001-07-25 2006-02-24 Microarray device with optimized indicator polynucleotides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US30791101P 2001-07-25 2001-07-25
US32991401P 2001-10-17 2001-10-17
US34329801P 2001-12-21 2001-12-21
US10/146,720 US7340349B2 (en) 2001-07-25 2002-05-14 Method and system for identifying splice variants of a gene
US10/272,461 US7833779B2 (en) 2001-07-25 2002-10-16 Methods and systems for polynucleotide detection
US11/361,627 US20060199208A1 (en) 2001-07-25 2006-02-24 Microarray device with optimized indicator polynucleotides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/272,461 Continuation US7833779B2 (en) 2001-07-25 2002-10-16 Methods and systems for polynucleotide detection

Publications (1)

Publication Number Publication Date
US20060199208A1 true US20060199208A1 (en) 2006-09-07

Family

ID=36944534

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/272,461 Expired - Fee Related US7833779B2 (en) 2001-07-25 2002-10-16 Methods and systems for polynucleotide detection
US11/361,627 Abandoned US20060199208A1 (en) 2001-07-25 2006-02-24 Microarray device with optimized indicator polynucleotides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/272,461 Expired - Fee Related US7833779B2 (en) 2001-07-25 2002-10-16 Methods and systems for polynucleotide detection

Country Status (1)

Country Link
US (2) US7833779B2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076959A1 (en) * 2001-07-25 2004-04-22 Subha Srinivasan Methods and systems for polynucleotide detection
WO2009007934A3 (en) * 2007-07-10 2009-05-07 Neurim Pharma 1991 Cd44 splice variants in neurodegenerative diseases

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030165931A1 (en) * 1998-03-11 2003-09-04 Bruno Tocque Qualitative differential screening
US6881571B1 (en) * 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US7361488B2 (en) * 2000-02-07 2008-04-22 Illumina, Inc. Nucleic acid detection methods using universal priming
US20060183136A1 (en) * 2004-11-05 2006-08-17 Genevieve Pont-Kingdon Method for haplotyping and genotyping by melting curve analysis of hybridization probes

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057410A (en) * 1988-08-05 1991-10-15 Cetus Corporation Chimeric messenger RNA detection methods
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6001567A (en) * 1996-01-24 1999-12-14 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6007231A (en) * 1996-08-14 1999-12-28 Academy Of Applied Science Method of computer aided automated diagnostic DNA test design, and apparatus therefor
US6100030A (en) * 1997-01-10 2000-08-08 Pioneer Hi-Bred International, Inc. Use of selective DNA fragment amplification products for hybridization-based genetic fingerprinting, marker assisted selection, and high-throughput screening
US6171793B1 (en) * 1999-04-19 2001-01-09 Affymetrix, Inc. Method for scanning gene probe array to produce data having dynamic range that exceeds that of scanner
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US20020048762A1 (en) * 1990-04-18 2002-04-25 N. V. Innogenetics S.A. Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of non-viral microorganisms
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20030040870A1 (en) * 2000-04-18 2003-02-27 Brooke Anderson Automated system and process for custom-designed biological array design and analysis
US20030097223A1 (en) * 1999-12-14 2003-05-22 Hitachi, Ltd. Primer design system
US6625545B1 (en) * 1997-09-21 2003-09-23 Compugen Ltd. Method and apparatus for mRNA assembly
US6632610B2 (en) * 2000-10-12 2003-10-14 Gensat S.A. Methods of identification and isolation of polynucleotides containing nucleic acid differences
US20030219805A1 (en) * 2002-03-13 2003-11-27 Zvi Kelman Detection of alternative and aberrant mRNA splicing
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US6881571B1 (en) * 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US6887662B1 (en) * 1999-11-29 2005-05-03 Diasorin Srl Oligonucleotides and assemblies thereof useful in the detection of the presence or absence of target nucleic acid sequences in a sample
US20050214824A1 (en) * 2000-04-25 2005-09-29 Affymetrix, Inc. Methods for monitoring the expression of alternatively spliced genes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224113T5 (en) 1994-02-16 2009-05-01 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services ANTIGEN POLYPEPTIDE ASSOCIATED WITH MELANOMA, EPITHOPOS OF THE SAME AND VACCINES AGAINST MELANOMA.
FR2775984B1 (en) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa QUALITATIVE DIFFERENTIAL SCREENING
GB9902776D0 (en) * 1999-02-08 1999-03-31 Marie Curie Cancer Care Materials and methods relating to a cancer cell marker
US20020048763A1 (en) 2000-02-04 2002-04-25 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7833779B2 (en) 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057410A (en) * 1988-08-05 1991-10-15 Cetus Corporation Chimeric messenger RNA detection methods
US20020048762A1 (en) * 1990-04-18 2002-04-25 N. V. Innogenetics S.A. Hybridization probes derived from the spacer region between the 16S and 23S rRNA genes for the detection of non-viral microorganisms
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6001567A (en) * 1996-01-24 1999-12-14 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6007231A (en) * 1996-08-14 1999-12-28 Academy Of Applied Science Method of computer aided automated diagnostic DNA test design, and apparatus therefor
US6100030A (en) * 1997-01-10 2000-08-08 Pioneer Hi-Bred International, Inc. Use of selective DNA fragment amplification products for hybridization-based genetic fingerprinting, marker assisted selection, and high-throughput screening
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
US6625545B1 (en) * 1997-09-21 2003-09-23 Compugen Ltd. Method and apparatus for mRNA assembly
US6881571B1 (en) * 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6171793B1 (en) * 1999-04-19 2001-01-09 Affymetrix, Inc. Method for scanning gene probe array to produce data having dynamic range that exceeds that of scanner
US6887662B1 (en) * 1999-11-29 2005-05-03 Diasorin Srl Oligonucleotides and assemblies thereof useful in the detection of the presence or absence of target nucleic acid sequences in a sample
US20030097223A1 (en) * 1999-12-14 2003-05-22 Hitachi, Ltd. Primer design system
US20020081590A1 (en) * 2000-02-04 2002-06-27 Aeomica, Inc. Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US20030040870A1 (en) * 2000-04-18 2003-02-27 Brooke Anderson Automated system and process for custom-designed biological array design and analysis
US20050214824A1 (en) * 2000-04-25 2005-09-29 Affymetrix, Inc. Methods for monitoring the expression of alternatively spliced genes
US6713257B2 (en) * 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US6632610B2 (en) * 2000-10-12 2003-10-14 Gensat S.A. Methods of identification and isolation of polynucleotides containing nucleic acid differences
US20030219805A1 (en) * 2002-03-13 2003-11-27 Zvi Kelman Detection of alternative and aberrant mRNA splicing

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040076959A1 (en) * 2001-07-25 2004-04-22 Subha Srinivasan Methods and systems for polynucleotide detection
US7833779B2 (en) 2001-07-25 2010-11-16 Jivan Biologies Inc. Methods and systems for polynucleotide detection
WO2009007934A3 (en) * 2007-07-10 2009-05-07 Neurim Pharma 1991 Cd44 splice variants in neurodegenerative diseases
US20110172286A1 (en) * 2007-07-10 2011-07-14 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
AU2008273713B2 (en) * 2007-07-10 2014-07-03 Neurim Pharmaceuticals (1991) Ltd. CD44 splice variants in neurodegenerative diseases
US9018180B2 (en) 2007-07-10 2015-04-28 Neurim Pharmaceuticals (1991) Ltd. CD44 splice variants in neurodegenerative diseases
US9416166B2 (en) 2007-07-10 2016-08-16 Neurim Pharmaceuticals (1991) Ltd. CD44 splice variants in neurodegenerative diseases

Also Published As

Publication number Publication date
US20040076959A1 (en) 2004-04-22
US7833779B2 (en) 2010-11-16

Similar Documents

Publication Publication Date Title
US10934576B2 (en) Profiling expression at transcriptome scale
EP2601611B1 (en) Methods for predicting stability and melting temperatures of nucleic acid duplexes
US20060199208A1 (en) Microarray device with optimized indicator polynucleotides
Kulcheski et al. The use of microRNAs as reference genes for quantitative polymerase chain reaction in soybean
Semagn et al. Single nucleotide polymorphism genotyping using Kompetitive Allele Specific PCR (KASP): overview of the technology and its application in crop improvement
Wan et al. Selection of appropriate reference genes for gene expression studies by quantitative real-time polymerase chain reaction in cucumber
Ballantyne et al. Locked nucleic acids in PCR primers increase sensitivity and performance
WO2006119439B1 (en) Compositions and methods for the analysis of degraded nucleic acids
EP3039594B1 (en) A quantum method for fluorescence background removal in dna melting analysis
Schwarz et al. Determination of detection and quantification limits for SNP allele frequency estimation in DNA pools using real time PCR
US20180032669A1 (en) Method for designing primer used for polymerase chain reaction and primer set
JP5272230B2 (en) Universal nucleic acid probe set and method of use thereof
Elvidge et al. Development and evaluation of real competitive PCR for high-throughput quantitative applications
US20060142952A1 (en) Microarray device for identifying splice variants of a gene
US8055451B2 (en) Method for estimating a melting temperature of a nucleic acid in buffers containing magnesium ions
US20070111207A1 (en) Partially double stranded nucleic acid molecules
Smylie et al. Analysis of sequence variations in several human genes using phosphoramidite bond DNA fragmentation and chip-based MALDI-TOF
EP1092782A3 (en) Genetic screening method and genetic screening apparatus
CN111808977A (en) Design method and detection method of specific primer of rifampicin antibiotic drug resistance gene caused by SNP
US8597938B2 (en) System for providing control reactions for real time RT-PCR
US9096896B2 (en) Method for quantifying DNA in a biological sample
Hendrickson et al. Accurate STR allele designations at the FGA and vWA loci despite primer site polymorphisms
WO2017056931A1 (en) Method for designing primers, primers, primer set, dna amplification method, and analysis method
Pérez et al. Comparative analysis of gene expression among species of different ploidy
CN102191314A (en) Low-cost, simple and high-efficient detection method of SNP based on PCR

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION